Gilead Sciences Profit Margin

The latest profit margin for GILD is -10.64% as of June 2026. That compares with 21.86% in the prior-year period — down 148.7% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Gilead Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, GILD's profit margin moved from 21.86% to -10.64% — a 148.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gilead Sciences's valuation or profitability profile.

Against Healthcare companies, GILD currently prints -10.64% for profit margin, while the sector average sits near 13.89%. That is roughly 176.6% below the sector mean. Large gaps often invite a closer look at Gilead Sciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Gilead Sciences converts resources into returns. At -10.64%, GILD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 21.86% in the prior-year period — down 148.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GILD's profit margin (-10.64%), review year-over-year change from 21.86%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.